TLR8 agonist partially improves IFN-γ deficiency of NK cells in chronic hepatitis B through the synergy of monocytes.
Xiulan AoQiaorong GanXuan HuangDongpeng BaoXuwei WuQiuxiang LinAifang LinYating DingLingxia WangYanping ChenZuxiong HuangPublished in: Alimentary pharmacology & therapeutics (2022)
In patients with CHB, targeting TLR8 partially rescues the IFN-γ insufficiency in NK cells. However, NK cells show an inhibitory response to TLR8 agonist stimulation. TLR8 agonist combined with NA may enhance the antiviral effect of NK cells.